XOMA Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the development and commercialization of innovative therapeutic solutions through a distinctive royalty aggregation strategy. The company actively partners with leading biopharmaceutical firms to enhance its diverse portfolio of therapies targeting a wide range of diseases, capitalizing on its expertise in antibody discovery and established clinical and regulatory frameworks. With operations that span the United States, Europe, and the Asia Pacific, XOMA is dedicated to advancing breakthroughs in biotechnology, ultimately striving to deliver transformative treatments that markedly improve patient outcomes. Show more

Location: 2200 POWELL STREET, EMERYVILLE, CA, UNITED STATES, 94608, EmeryVille, CA, 94608, USA | Website: https://www.xoma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

327.8M

52 Wk Range

$18.35 - $39.92

Previous Close

$26.47

Open

$26.45

Volume

224,305

Day Range

$26.16 - $27.87

Enterprise Value

413M

Cash

90.48M

Avg Qtr Burn

-296K

Insider Ownership

1.70%

Institutional Own.

68.20%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XmAb942 (Xtend™ anti-TL1A) Details Ulcerative colitis	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vudalimab (PD-1 x CTLA-4) Details Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vudalimab (PD-1 x CTLA-4) Details Castration-resistant prostate cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb564 (IL2-Fc) Details Atopic dermatitis, Psoriasis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb541 Details Cancer, Ovarian cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XmAb662 (IL12-Fc) Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Plamotamab (CD20 x CD3) +tafasitamab plus lenalidomide Details Cancer, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.